Rosenblum Silverman Sutton S F Inc. CA Sells 185 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Rosenblum Silverman Sutton S F Inc. CA reduced its stake in IQVIA Holdings Inc. (NYSE:IQV) by 1.0% during the 4th quarter, Holdings Channel reports. The firm owned 17,583 shares of the medical research company’s stock after selling 185 shares during the period. Rosenblum Silverman Sutton S F Inc. CA’s holdings in IQVIA were worth $3,455,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in IQV. Smith Group Asset Management LLC bought a new position in IQVIA during the fourth quarter worth about $1,616,000. Nordea Investment Management AB boosted its stake in IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after acquiring an additional 452,029 shares during the last quarter. Hickory Asset Management Inc. acquired a new position in IQVIA during the fourth quarter valued at approximately $941,000. Fifth Third Bancorp increased its stake in IQVIA by 13.0% in the fourth quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock valued at $2,590,000 after purchasing an additional 1,521 shares in the last quarter. Finally, Graphene Investments SAS boosted its position in shares of IQVIA by 22.0% during the fourth quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company’s stock worth $2,948,000 after purchasing an additional 2,700 shares in the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Stock Performance

Shares of IQVIA stock opened at $167.62 on Friday. The stock has a market cap of $29.55 billion, a price-to-earnings ratio of 22.35, a P/E/G ratio of 1.99 and a beta of 1.46. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a twelve month low of $166.11 and a twelve month high of $252.88. The company’s fifty day moving average is $190.67 and its 200 day moving average is $204.66.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently commented on IQV. Royal Bank of Canada restated an “outperform” rating and issued a $270.00 price objective on shares of IQVIA in a research report on Monday, February 10th. StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a research report on Wednesday, March 12th. Barclays dropped their target price on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd. Morgan Stanley boosted their price target on IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a report on Tuesday, February 11th. Finally, BTIG Research cut shares of IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. Five research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $249.05.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.